434 related articles for article (PubMed ID: 30269082)
21. Characterization of PI3KCA and BRAF mutations in gastric adenocarcinoma: An approach to a personalized targeted therapy for Moroccan HER2 overexpressed patients.
Joutei HAH; Marchoudi N; Mahfoud W; Sadaoui I; Fechtali T; Benomar H
Arab J Gastroenterol; 2018 Dec; 19(4):155-158. PubMed ID: 30503528
[TBL] [Abstract][Full Text] [Related]
22. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
23. Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Mishima Y; Matsusaka S; Chin K; Mikuniya M; Minowa S; Takayama T; Shibata H; Kuniyoshi R; Ogura M; Terui Y; Mizunuma N; Hatake K
Target Oncol; 2017 Jun; 12(3):341-351. PubMed ID: 28508152
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
Yagi S; Wakatsuki T; Yamamoto N; Chin K; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Shinozaki E; Suenaga M; Fujisaki J; Ishikawa Y; Yamaguchi K; Namikawa K; Horiuchi Y
Gastric Cancer; 2019 May; 22(3):518-525. PubMed ID: 30328533
[TBL] [Abstract][Full Text] [Related]
25. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.
Maron SB; Chatila W; Walch H; Chou JF; Ceglia N; Ptashkin R; Do RKG; Paroder V; Pandit-Taskar N; Lewis JS; Biachi De Castria T; Sabwa S; Socolow F; Feder L; Thomas J; Schulze I; Kim K; Elzein A; Bojilova V; Zatzman M; Bhanot U; Nagy RJ; Lee J; Simmons M; Segal M; Ku GY; Ilson DH; Capanu M; Hechtman JF; Merghoub T; Shah S; Schultz N; Solit DB; Janjigian YY
Clin Cancer Res; 2023 Sep; 29(18):3633-3640. PubMed ID: 37406106
[TBL] [Abstract][Full Text] [Related]
26. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer.
Matsushita D; Uenosono Y; Arigami T; Yanagita S; Okubo K; Kijima T; Miyazono F; Hamanoue M; Hokita S; Nakashima S; Ohtsuka T; Natsugoe S
Cancer Chemother Pharmacol; 2021 Jun; 87(6):789-797. PubMed ID: 33641065
[TBL] [Abstract][Full Text] [Related]
28. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.
Lee JY; Hong M; Kim ST; Park SH; Kang WK; Kim KM; Lee J
Sci Rep; 2015 Mar; 5():9289. PubMed ID: 25786580
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.
Wakatsuki T; Yamamoto N; Sano T; Chin K; Kawachi H; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Matsushima T; Suenaga M; Shinozaki E; Hiki N; Ishikawa Y; Yamaguchi K
J Gastroenterol; 2018 Nov; 53(11):1186-1195. PubMed ID: 29633013
[TBL] [Abstract][Full Text] [Related]
30. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
Cho JH; Lim JY; Cho JY
World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
[TBL] [Abstract][Full Text] [Related]
31.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
32. Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2-Positive Advanced Gastric Cancer.
Yamaguchi K; Ito M; Isobe T; Koreishi S; Taguchi R; Uehara K; Ueno S; Imajima T; Kitazono T; Tsuchihashi K; Ohmura H; Yoshihiro T; Tanoue K; Nishiyori S; Iwama E; Maeda T; Akashi K; Baba E
JCO Precis Oncol; 2024 May; 8():e2300681. PubMed ID: 38748981
[TBL] [Abstract][Full Text] [Related]
33. Personalized therapeutic strategies in HER2-driven gastric cancer.
Ughetto S; Migliore C; Pietrantonio F; Apicella M; Petrelli A; D'Errico L; Durando S; Moya-Rull D; Bellomo SE; Rizzolio S; Capelôa T; Ribisi S; Degiuli M; Reddavid R; Rapa I; Fumagalli U; De Pascale S; Ribero D; Baronchelli C; Sgroi G; Rausa E; Baiocchi GL; Molfino S; Manenti S; Bencivenga M; Sacco M; Castelli C; Siena S; Sartore-Bianchi A; Tosi F; Morano F; Raimondi A; Prisciandaro M; Gloghini A; Marsoni S; Sottile A; Sarotto I; Sapino A; Marchiò C; Cassoni P; Guarrera S; Corso S; Giordano S
Gastric Cancer; 2021 Jul; 24(4):897-912. PubMed ID: 33755862
[TBL] [Abstract][Full Text] [Related]
34. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
[TBL] [Abstract][Full Text] [Related]
35. Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.
Gonzalez-Alonso P; Cristobal I; Zazo S; Martin-Aparicio E; Chamizo C; Madoz-Gurpide J; Rovira A; Eroles P; Lluch A; Albanell J; Rojo F
Curr Med Chem; 2018; 25(17):1976-1998. PubMed ID: 27993109
[TBL] [Abstract][Full Text] [Related]
36. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
[TBL] [Abstract][Full Text] [Related]
37. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
[TBL] [Abstract][Full Text] [Related]
38. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
39. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.
Siravegna G; Lazzari L; Crisafulli G; Sartore-Bianchi A; Mussolin B; Cassingena A; Martino C; Lanman RB; Nagy RJ; Fairclough S; Rospo G; Corti G; Bartolini A; Arcella P; Montone M; Lodi F; Lorenzato A; Vanzati A; Valtorta E; Cappello G; Bertotti A; Lonardi S; Zagonel V; Leone F; Russo M; Balsamo A; Truini M; Di Nicolantonio F; Amatu A; Bonazzina E; Ghezzi S; Regge D; Vanzulli A; Trusolino L; Siena S; Marsoni S; Bardelli A
Cancer Cell; 2018 Jul; 34(1):148-162.e7. PubMed ID: 29990497
[TBL] [Abstract][Full Text] [Related]
40. The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Toomey S; Madden SF; Furney SJ; Fan Y; McCormack M; Stapleton C; Cremona M; Cavalleri GL; Milewska M; Elster N; Carr A; Fay J; Kay EW; Kennedy S; Crown J; Gallagher WM; Hennessy BT; Eustace AJ
Oncotarget; 2016 Nov; 7(46):75518-75525. PubMed ID: 27776352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]